Internal Medicine, Rheumatology · Fishkill, NY
NPI
1811146236
Since 2008
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
200 Westage Business Ctr Dr, Suite 115
Fishkill, NY, 12524
Phone (845) 897-8717
Groups this clinician bills Medicare through
Medicare paid, 2024
$435K
83,931 services
Medicare patients, 2024
498
Average age 73
Drug cost, 2024
$6.8M
4,572 prescriptions
Company payments, 2025
$2,318
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Umesh Patel was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 81,600 times for 23 patients. In total Umesh Patel billed 83,931 services in 15 codes, and Medicare paid $435K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-03-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 81,600 | 23 | $3.62 | $296K |
| 99214 Office E&M - Established | Office | 710 | 272 | $95.86 | $68K |
| 99214 Office E&M - Established | Facility | 374 | 197 | $73.20 | $27K |
| 96372 Injection Administration | Office | 253 | 27 | $10.89 | $2,754 |
| 96401 Chemotherapy Administration | Office | 158 | 21 | $58.28 | $9,208 |
| 99204 Office E&M - New | Office | 94 | 94 | $127.59 | $12K |
| 99213 Office E&M - Established | Office | 49 | 41 | $66.44 | $3,256 |
| 99204 Office E&M - New | Facility | 37 | 37 | $103.32 | $3,823 |
| 99442 Telephone Services | Office | 32 | 23 | $69.41 | $2,221 |
| 99213 Office E&M - Established | Facility | 31 | 31 | $46.87 | $1,453 |
By year: 2022 $405K for 62,791 services; 2023 $438K for 80,748 services; 2024 $435K for 83,931 services.
Medicare prescription drug claims, 2024
In 2024, the drug Umesh Patel prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 667 prescriptions and refills. In total Umesh Patel wrote 4,572 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 667 | 1,583 | 218 | $20K |
| Leflunomide Generic | 438 | 1,008 | 139 | $27K |
| Hydroxychloroquine Sulfate Generic | 337 | 771 | 111 | $14K |
| Enbrel Sureclick Etanercept | 334 | 370 | 49 | $2.8M |
| Prednisone Generic | 331 | 547 | 116 | $2,236 |
| Humira(Cf) Pen Adalimumab | 155 | 175 | 23 | $1.3M |
| Duloxetine Hcl Generic | 151 | 277 | 41 | $2,452 |
| Folic Acid Generic | 130 | 346 | 40 | $1,181 |
| Allopurinol Generic | 129 | 343 | 43 | $1,640 |
| Tramadol Hcl Generic | 113 | 113 | 21 | $628 |
| Gabapentin Generic | 101 | 173 | 34 | $890 |
| Cyclobenzaprine Hcl Generic | 100 | 170 | 44 | $958 |
| Otezla Apremilast | 98 | 102 | 18 | $473K |
| Meloxicam Generic | 81 | 139 | 27 | $417 |
| Febuxostat Generic | 67 | 110 | 14 | $4,656 |
Brand drugs: - claims; generic drugs: 3,643 claims; opioid claims: 214.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Umesh Patel $2,318 ($2,318 in general payments such as food, travel and fees) from 14 companies. The largest payer was Amgen Inc. with $512.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 21 | $512 |
| Abbvie Inc. ABBV | 21 | $495 |
| Janssen Biotech, Inc. JNJ | 16 | $408 |
| UCB, Inc. UCB.BR | 12 | $239 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $150 |
| GlaxoSmithKline, LLC. GSK | 6 | $112 |
| Lilly USA, LLC LLY | 4 | $79.38 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $70.66 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $59.26 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $55.77 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.